Obesity Management 2015

San Diego, CA US

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists and endocrine fellows, primary care and internal medicine physicians, physician's assistants, nurse practitioners and other healthcare professionals treating overweight and obese individuals.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

Gut Microbiome and Obesity

  • Explain the relation of gut microbiota in the risk of diabetes and potential treatment pathway

What is New in Behavioral Weight Loss

  • Describe the role of hormonal and neural mechanisms in the regulation of appetite, food intake, and body weight
  • Recognize the behavioral approaches to obesity management that are most impactful in practice

Physical Activity in Health Promotion and Weight Management             

  • Develop an approach to choosing a treatment strategy that is most optimal for managing obesity

Pharmacological Management of the Obese Patient

  • Describe the role of hormonal and neural mechanisms in the regulation of appetite, food intake, and body weight
  • Apply updated practice guidelines in a clinical setting

Pediatric Obesity            

  • Describe the best treatment strategies for overweight and obese youth

Approaches to Promoting Behavior Change               

  • Explain the methods available for promoting lasting behavior change
  • Describe the most common issues in behavior change

Clinical Significance of Obstructive Sleep Apnea

  • Discuss the benefits of weight loss on cardiovascular health
  • Evaluate patients for sleep apnea and discuss possible treatment strategies

Co-Management of Obesity and Diabetes: Case Studies

  • Select appropriate medical therapy options for the co-management of diabetes and obesity

Weight Loss Maintenance

  • Identify the clinical and behavioral barriers to achieving weight loss and preventing weight gain in overweight and obese patients
  • Explain the clinical benefits of losing 5% to 10% of excess body weight

Obesity and NAFLD                 

  • Explain the pathogenesis and pathophysiology of NAFLD
  • Discuss the most effective treatment options for patients with NAFLD

Metabolic Surgery: Mechanisms and Novel Insights into Glucose Metabolism

  • Explain the comparative effectiveness of the surgical treatments for obesity, including what is known about mechanisms of action

Weight Loss Surgery and Outcomes: Which Procedure, Who Benefits?        

  • Define medically significant weight loss and its impact on glycemic parameters

The Pre- and Post-Operative Care of the Bariatric Surgery Patient

  • Recognize the appropriate provocative test to evaluate hypoglycemia from bariatric surgery
  • Diagnose and manage dumping syndrome

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Interpersonal and Communication Skills
Topic Area: 
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Quality Improvement and Healthcare Delivery
Health Disparities
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 6.50 AMA PRA Category 1 Credits
  • 6.50 CME Certificate of Participation
Course opens: 
Course expires: 
San Diego Convention Center
111 W Harbor Dr
San Diego, CA 92101
United States

Program Chairs

Daniel Bessesen, MD; Univ of Colorado Sch of Med
Marc Cornier, MD; Univ of Colorado Sch of Med
Jonathan Purnell, MD; Oregon Health and Sciences Univ
Steven Smith, MD; Florida Hosp/Translational Research Inst for Metabolism and Diabetes


Caroline Apovian, MD; Boston Univ
Sonia Caprio, MD; Yale Univ
W Timothy Garvey, MD; Univ of Alabama
John Jakicic, PhD; Univ of Pittsburgh
Samuel Klein, MD; Washington Univ
Rosa Krajmalnik-Brown, PhD; Arizona State Univ
Blandine Laferrere, MD; Columbia Univ
Ninh Nguyen, MD; Univ of California, Irvine
Patrick O’Neil, PhD; Med Univ of South Carolina
Naresh M Punjabi, MD; Johns Hopkins Univ
Donna Ryan, MD; Pennington Biomedical Research Center
Christopher Still, DO; Geisinger Obesity Institute
Holly Wyatt, MD; Univ of Colorado


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Caroline Apovian, MD: Advisory Group Member, Amylin Pharmaceuticals, Johnson & Johnson, Merck & Co., Novo Nordisk, Nutrisystem, Pfizer, Inc.; Investigator, Aspire Bariatrics, Eli Lilly & Co., GI Dynamics, Orexigen; Speaker Bureau Member, Takeda

W Timothy Garvey, MD: Ad Hoc Consultant and Clinical Researcher, AstraZeneca; Advisory Group Member, Boehringer Ingelheim, Daiichi Sankyo, Jansen Pharmaceuticals, Liposcience, Novo Nordisk, Takeda, Vivus USA; Advisory Group Member and Clinical Researcher, Eisai; Clinical Researcher, Merck & Co., Sanofi, Weight Watchers

Donna Ryan, MD: Advisory Group Member, Real Appeal; Advisory Group Member and Speaker, Novo Nordisk, Takeda, Vivus USA; Advisory Group Member and Speaker Bureau Member, Eisai; Consultant, Scientific Intake

The following faculty reported no relevant financial relationships:

Daniel Bessesen, MD; Sonia Caprio, MD; Marc Cornier, MD; John Jakicic, PhD; Samuel Klein, MD; Rosa Krajmalnik-Brown, PhD; Blandine Laferrere, MD; Ninh Nguyen, MD; Patrick O’Neil, PhD; Naresh M Punjabi, MD; Jonathan Purnell, MD; Steven Smith, MD; Christopher Still, DO; Holly Wyatt, MD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 6.50 AMA PRA Category 1 Credits
  • 6.50 CME Certificate of Participation